Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101


Serum Testosterone 60 Months after Passive-Scatter Proton Therapy for Localized Prostate Cancer.

Nichols RC, Morris CG, Bryant C, Hoppe BS, Henderson RH, Mendenhall WM, Li Z, Costa JA, Williams CR, Mendenhall NP.

Cancer Invest. 2019;37(2):85-89. doi: 10.1080/07357907.2019.1565766. Epub 2019 Mar 5.


Hypofractionated passively scattered proton radiotherapy for low- and intermediate-risk prostate cancer is not associated with post-treatment testosterone suppression.

Kil WJ, Nichols RC Jr, Hoppe BS, Morris CG, Marcus RB Jr, Mendenhall W, Mendenhall NP, Li Z, Costa JA, Williams CR, Henderson RH.

Acta Oncol. 2013 Apr;52(3):492-7. doi: 10.3109/0284186X.2013.767983.


Proton radiotherapy for prostate cancer is not associated with post-treatment testosterone suppression.

Nichols RC Jr, Morris CG, Hoppe BS, Henderson RH, Marcus RB Jr, Mendenhall WM, Li Z, Williams CR, Costa JA, Mendenhall NP.

Int J Radiat Oncol Biol Phys. 2012 Mar 1;82(3):1222-6. doi: 10.1016/j.ijrobp.2010.12.025. Epub 2011 May 11.


Five-Year Biochemical Results, Toxicity, and Patient-Reported Quality of Life After Delivery of Dose-Escalated Image Guided Proton Therapy for Prostate Cancer.

Bryant C, Smith TL, Henderson RH, Hoppe BS, Mendenhall WM, Nichols RC, Morris CG, Williams CR, Su Z, Li Z, Lee D, Mendenhall NP.

Int J Radiat Oncol Biol Phys. 2016 May 1;95(1):422-34. doi: 10.1016/j.ijrobp.2016.02.038. Epub 2016 Feb 16.


Serum testosterone levels after external beam radiation for clinically localized prostate cancer.

Zagars GK, Pollack A.

Int J Radiat Oncol Biol Phys. 1997 Aug 1;39(1):85-9.


Serum testosterone--a significant determinant of metastatic relapse for irradiated localized prostate cancer.

Zagars GK, Pollack A, von Eschenbach AC.

Urology. 1997 Mar;49(3):327-34.


A Prospective Comparison of the Effects of Interfractional Variations on Proton Therapy and Intensity Modulated Radiation Therapy for Prostate Cancer.

Moteabbed M, Trofimov A, Sharp GC, Wang Y, Zietman AL, Efstathiou JA, Lu HM.

Int J Radiat Oncol Biol Phys. 2016 May 1;95(1):444-53. doi: 10.1016/j.ijrobp.2015.12.366. Epub 2015 Dec 29.


Testosterone Therapy after Radiation Therapy for Low, Intermediate and High Risk Prostate Cancer.

Pastuszak AW, Khanna A, Badhiwala N, Morgentaler A, Hult M, Conners WP, Sarosdy MF, Yang C, Carrion R, Lipshultz LI, Khera M.

J Urol. 2015 Nov;194(5):1271-6. doi: 10.1016/j.juro.2015.05.084. Epub 2015 May 27.


Proton Therapy as Salvage Treatment for Local Relapse of Prostate Cancer Following Cryosurgery or High-Intensity Focused Ultrasound.

Holtzman AL, Hoppe BS, Letter HP, Bryant C, Nichols RC, Henderson RH, Mendenhall WM, Morris CG, Williams CR, Li Z, Mendenhall NP.

Int J Radiat Oncol Biol Phys. 2016 May 1;95(1):465-71. doi: 10.1016/j.ijrobp.2015.12.351. Epub 2015 Dec 19.


Determining dosing intervals for luteinizing hormone releasing hormone agonists based on serum testosterone levels: a prospective study.

Pathak AS, Pacificar JS, Shapiro CE, Williams SG.

J Urol. 2007 Jun;177(6):2132-5; discussion 2135.


Inclusion of a variable RBE into proton and photon plan comparison for various fractionation schedules in prostate radiation therapy.

Ödén J, Eriksson K, Toma-Dasu I.

Med Phys. 2017 Mar;44(3):810-822. doi: 10.1002/mp.12117.


Potency preservation following stereotactic body radiation therapy for prostate cancer.

Obayomi-Davies O, Chen LN, Bhagat A, Wright HC, Uhm S, Kim JS, Yung TM, Lei S, Batipps GP, Pahira J, McGeagh KG, Collins BT, Kowalczyk K, Bandi G, Kumar D, Suy S, Dritschilo A, Lynch JH, Collins SP.

Radiat Oncol. 2013 Nov 1;8:256. doi: 10.1186/1748-717X-8-256.


Low incidence of new biochemical hypogonadism after intensity modulated radiation therapy for prostate cancer.

Markovina S, Weschenfelder DC, Gay H, McCandless A, Carey B, DeWees T, Knutson N, Michalski J.

Pract Radiat Oncol. 2014 Nov-Dec;4(6):430-6. doi: 10.1016/j.prro.2014.02.004. Epub 2014 May 17.


Sperm preservation and neutron contamination following proton therapy for prostate cancer study.

Hoppe BS, Harris S, Rhoton-Vlasak A, Bryant C, Morris CG, Dagan R, Nichols RC, Mendenhall WM, Henderson RH, Li Z, Mendenhall NP.

Acta Oncol. 2017 Jan;56(1):17-20. doi: 10.1080/0284186X.2016.1205219. Epub 2016 Jul 15.


Baseline serum testosterone in men treated with androgen deprivation therapy and radiotherapy for localized prostate cancer.

Roach M 3rd, Bae K, Lawton C, Donnelly BJ, Grignon D, Hanks GE, Porter A, Lepor H, Venketesan V, Sandler H.

Int J Radiat Oncol Biol Phys. 2010 Dec 1;78(5):1314-22. doi: 10.1016/j.ijrobp.2009.09.073. Epub 2010 Apr 8.


Nadir Testosterone after Long-Term Followup Predicts Prognosis in Patients with Prostate Cancer Treated with Combined Androgen Blockade.

Kamada S, Sakamoto S, Ando K, Muroi A, Fuse M, Kawamura K, Imamoto T, Suzuki H, Nagata M, Nihei N, Akakura K, Ichikawa T.

J Urol. 2015 Nov;194(5):1264-70. doi: 10.1016/j.juro.2015.03.120. Epub 2015 Apr 7.


Evaluation of the serum testosterone to prostate-specific antigen ratio as a predictor of prostate cancer risk.

Morote J, Planas J, Ramirez C, Gómez E, Raventós CX, Placer J, Catalán R, de Torres IM.

BJU Int. 2010 Feb;105(4):481-4. doi: 10.1111/j.1464-410X.2009.08761.x. Epub 2009 Aug 13.


Quality of life and toxicity from passively scattered and spot-scanning proton beam therapy for localized prostate cancer.

Pugh TJ, Munsell MF, Choi S, Nguyen QN, Mathai B, Zhu XR, Sahoo N, Gillin M, Johnson JL, Amos RA, Dong L, Mahmood U, Kuban DA, Frank SJ, Hoffman KE, McGuire SE, Lee AK.

Int J Radiat Oncol Biol Phys. 2013 Dec 1;87(5):946-53. doi: 10.1016/j.ijrobp.2013.08.032. Epub 2013 Oct 15.


Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy.

Morote J, Orsola A, Planas J, Trilla E, Raventós CX, Cecchini L, Catalán R.

J Urol. 2007 Oct;178(4 Pt 1):1290-5. Epub 2007 Aug 14.


Supplemental Content

Support Center